

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/RFEFF89DE91EN.html>

Date: August 2018

Pages: 75

Price: US\$ 3,500.00 (Single User License)

ID: RFEFF89DE91EN

Abstracts

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2018

SUMMARY

According to the recently published report 'Retinoic Acid Receptor Gamma - Pipeline Review, H2 2018'; Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes close to 21 molecules.

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for limb bud development.

The report 'Retinoic Acid Receptor Gamma - Pipeline Review, H2 2018' outlays comprehensive information on the Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 5, 6, 7 and 1 respectively.

Report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Immunology, Oncology, Ophthalmology, Respiratory, Gastrointestinal and Genetic Disorders which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Allergies, Autoimmune Disorders, Congenital Ichthyosis, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Gorlin Syndrome (Basal Cell Nevus Syndrome/Nevoid Basal Cell Carcinoma Syndrome), Head And Neck Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Multiple Hereditary Exostoses, Plaque Psoriasis (Psoriasis Vulgaris) and Retinopathy Of Prematurity.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)

The report reviews Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Retinoic Acid Receptor Gamma (RAR

Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects

The report assesses Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B

Member 3 or NR1B3 or RARG) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Overview

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Companies Involved in Therapeutics Development

3SBio Inc

Bausch Health Companies Inc

Boehringer Ingelheim GmbH

Clementia Pharmaceuticals Inc

Galderma SA

Lee's Pharmaceutical Holdings Ltd

Phosphagenics Ltd

Promius Pharma LLC

Sol-Gel Technologies Ltd

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Drug Profiles

(adapalene + benzoyl peroxide + clindamycin phosphate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(adapalene + clindamycin hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(benzoyl peroxide + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(benzoyl peroxide + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(clindamycin phosphate + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(halobetasol propionate + tazarotene) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(TPX-6001 + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alitretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bexarotene + CD1530 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palovarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Autoimmune and Allergic Disorders -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal
Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize RARG for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal

Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trifarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Dormant Products

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Discontinued Products

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Product Development Milestones

Featured News & Press Releases

Jun 18, 2018: FDA declines to approve Valeant's plaque psoriasis lotion

Jun 18, 2018: FDA Issues Complete Response Letter For DUOBRII (Halobetasol Propionate and Tazarotene) Lotion

May 23, 2018: Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP

Apr 20, 2018: Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple Osteochondromas

Apr 09, 2018: Ortho Dermatologics Announces Publication of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII In The Journal of the American Academy of Dermatology

Feb 15, 2018: Sol-Gel's Phase 2 Data on TWIN to be Presented at the 2018 American Academy of Dermatology Annual Meeting

Jan 12, 2018: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form

Dec 12, 2017: Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva

Nov 20, 2017: Preclinical study demonstrates promising treatment for rare bone disease

Nov 09, 2017: Promius Pharma Initiates Phase 3 Clinical Trials of DFD-03 for The Treatment of Acne Vulgaris

Nov 02, 2017: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment

Sep 05, 2017: Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118

Aug 31, 2017: Clementia Announces Data Presentations at Upcoming Medical Conferences in September

Jul 20, 2017: Sol-Gel Announces Positive Phase 2 Clinical Trial Results for TWIN in Patients with Acne Vulgaris

Jun 05, 2017: Clementia Pharmaceuticals to Host Symposium at the 8th International

Conference on Children's Bone Health

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by 3SBio Inc, H2 2018
Pipeline by Bausch Health Companies Inc, H2 2018
Pipeline by Boehringer Ingelheim GmbH, H2 2018
Pipeline by Clementia Pharmaceuticals Inc, H2 2018
Pipeline by Galderma SA, H2 2018
Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018
Pipeline by Phosphagenics Ltd, H2 2018
Pipeline by Promius Pharma LLC, H2 2018
Pipeline by Sol-Gel Technologies Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

3SBio Inc

Bausch Health Companies Inc

Boehringer Ingelheim GmbH

Clementia Pharmaceuticals Inc

Galderma SA

Lee's Pharmaceutical Holdings Ltd

Phosphagenics Ltd

Promius Pharma LLC

Sol-Gel Technologies Ltd

I would like to order

Product name: Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/RFEFF89DE91EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RFEFF89DE91EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

